N-Ethyltryptamine

{{Short description|Chemical compound}}

{{DISPLAYTITLE:N-Ethyltryptamine}}

{{Drugbox

| verifiedrevid = 447115197

| drug_name = N-Ethyltryptamine

| image = N-Ethyltryptamine.png

| width = 200px

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| routes_of_administration =

| ATC_prefix = None

| ATC_suffix =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US = Schedule I (isomer of DMT)

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 61-53-0

| PubChem = 6092

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 5867

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = M6X6KY3BQH

| synonyms = NET; NETP; Ethyltryptamine

| IUPAC_name = N-ethyl-2-(1H-indol-3-yl)ethan-1-amine

| C=12 | H=16 | N=2

| SMILES = CCNCCc1c[nH]c2ccccc12

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C12H16N2/c1-2-13-8-7-10-9-14-12-6-4-3-5-11(10)12/h3-6,9,13-14H,2,7-8H2,1H3

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = TZWUSTVNAVKAPA-UHFFFAOYSA-N

| melting_point = 87

| melting_high = 88

}}

N-Ethyltryptamine (NET) is a tryptamine that is structurally related to N-methyltryptamine (NMT) and the psychedelic drugs N,N-dimethyltryptamine (DMT) and N,N-diethyltryptamine (DET).[http://www.erowid.org/library/books_online/tihkal/tihkal49.shtml NET Entry in TIHKAL]

It has been found to act as a potent serotonin 5-HT_2A receptor full agonist and serotonin releasing agent.{{cite journal | vauthors = Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB | title = Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes | journal = Psychopharmacology (Berl) | volume = 231 | issue = 21 | pages = 4135–4144 | date = October 2014 | pmid = 24800892 | pmc = 4194234 | doi = 10.1007/s00213-014-3557-7 | url = }}

Alexander Shulgin included NET as an entry in TiHKAL. However, he stated that it had been subjected only to modest human trials and that no active dose level had been identified.